- Home
- ELVN vs SLRC Comparison
ELVN vs SLRC Comparison
Compare ELVN & SLRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- SLRC
- Stock Information
- Founded
- ELVN 2016
- SLRC 2007
- Country
- ELVN United States
- SLRC United States
- Employees
- ELVN N/A
- SLRC N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- SLRC Finance/Investors Services
- Sector
- ELVN Health Care
- SLRC Finance
- Exchange
- ELVN Nasdaq
- SLRC Nasdaq
- Market Cap
- ELVN 927.8M
- SLRC 889.2M
- IPO Year
- ELVN 2020
- SLRC 2010
- Fundamental
- Price
- ELVN $17.77
- SLRC $16.76
- Analyst Decision
- ELVN Strong Buy
- SLRC Hold
- Analyst Count
- ELVN 4
- SLRC 6
- Target Price
- ELVN $37.25
- SLRC $15.79
- AVG Volume (30 Days)
- ELVN 361.5K
- SLRC 137.9K
- Earning Date
- ELVN 05-14-2025
- SLRC 05-07-2025
- Dividend Yield
- ELVN N/A
- SLRC 9.79%
- EPS Growth
- ELVN N/A
- SLRC N/A
- EPS
- ELVN N/A
- SLRC 1.61
- Revenue
- ELVN N/A
- SLRC $227,510,000.00
- Revenue This Year
- ELVN N/A
- SLRC N/A
- Revenue Next Year
- ELVN N/A
- SLRC N/A
- P/E Ratio
- ELVN N/A
- SLRC $10.41
- Revenue Growth
- ELVN N/A
- SLRC N/A
- 52 Week Low
- ELVN $13.30
- SLRC $13.64
- 52 Week High
- ELVN $30.03
- SLRC $17.94
- Technical
- Relative Strength Index (RSI)
- ELVN 49.54
- SLRC 61.92
- Support Level
- ELVN $15.81
- SLRC $16.21
- Resistance Level
- ELVN $17.54
- SLRC $16.80
- Average True Range (ATR)
- ELVN 1.30
- SLRC 0.24
- MACD
- ELVN -0.04
- SLRC 0.05
- Stochastic Oscillator
- ELVN 38.06
- SLRC 91.28
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.